Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.49 |
| ▸ | CCNC | P24863 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18935522 | 0.92 | MTNR1A (0.51) | BRD4CCNCCDK8DYRK1AMTNR1A | |
| SCHEMBL18918073 | 0.86 | CYP2A6 (0.43) | BRD4HDAC6HDAC1HDAC8MGLL | |
| SCHEMBL17997425 | 0.84 | MTNR1A (0.60) | BRD4HDAC6DYRK1AHDAC1HDAC8 | |
| SCHEMBL17294058 | 0.82 | CYP2A6 (0.44) | BRD4DYRK1AMTNR1AMTNR1BDRD2 | |
| SCHEMBL18938904 | 0.82 | MTNR1A (0.44) | BRD4DYRK1AMTNR1AMTNR1BDRD2 | |
| SCHEMBL18927041 | 0.82 | BRD4 (0.49) | BRD4DYRK1AMTNR1AMTNR1BDRD2 | |
| SCHEMBL18917851 | 0.81 | BRD4 (0.51) | BRD4MGLLMTNR1AMTNR1B | |
| SCHEMBL3417837 | 0.79 | MTNR1A (0.50) | BRD4MTNR1AMTNR1B | |
| SCHEMBL28180030 | 0.79 | CCNC (0.42) | BRD4CCNCCDK8DYRK1ADRD2 | |
| SCHEMBL20436342 | 0.78 | HTR2A (0.45) | HDAC6HDAC1HDAC8MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170158702-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KYRAS THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158702-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KRAS, HRAS, NRAS | BRD4 359/4885CCNC 348/4885CDK8 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.